• Kanamycin Sulfate in Anti-Virulence Assays

  2026-09-08

  Kanamycin Sulfate is more than a selection reagent: it can serve as a controlled experimental variable in microbiome and anti-virulence research. This guide connects aminoglycoside mechanism, assay controls, and insights from a recent Clostridioides difficile toxin study.

• Fluo-4 AM for Calcium Imaging in Bioelectronic Research

  2026-09-08

  Fluo-4 AM converts transient Ca2+ activity into a practical readout for cell signaling, pharmacological testing, and device-linked neurobiology. This workflow shows how to pair a fast, bright fluorescent calcium indicator with functional assays inspired by an adaptive retinal prosthesis study.

• Vemurafenib (PLX4032) in Melanoma Research

  2026-09-07

  Vemurafenib, also called PLX4032, is a selective BRAF kinase inhibitor used to study BRAF V600-mutant melanoma biology. Its defined biochemical potency, genotype-dependent signaling effects, and documented xenograft activity make it useful for melanoma cell proliferation inhibition and resistance research.

• Cyanine 5-dCTP: Signal-Aware DNA Labeling

  2026-09-07

  Cyanine 5-dCTP enables red-fluorescent DNA labeling while preserving a clear view of enzymatic synthesis performance. This article connects Cy5-dCTP chemistry with DNA-framework-assisted synthesis, assay design, controls, and practical interpretation.

• Imatinib (STI571): Kinase Assay Workflows

  2026-09-05

  Imatinib (STI571) provides a practical way to separate Abl, PDGF receptor, and c-Kit signaling from downstream proliferation effects. This workflow-focused guide connects kinase inhibition assays with erythroleukemia differentiation research, emphasizing concentration control, phospho-readouts, combination studies, and troubleshooting.

• Dual HER2–VEGFR2 Targeting in TNBC

  2026-09-04

  The reference study evaluates lapatinib plus Telatinib (BAY 57-9352) in the HER2-negative, triple-negative breast cancer model MDA-MB-231. Its central contribution is a phenotype-focused in vitro analysis linking dual kinase inhibition with reduced proliferation, invadopodia formation, and 2D angiogenic tube formation, while leaving target engagement, pharmacological synergy, and in vivo relevance unresolved.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-04

  Masitinib (AB1010) is a DMSO-compatible phenylaminothiazole-type tyrosine kinase inhibitor for controlled KIT, PDGFRα, and PDGFRβ studies. It is appropriate for targeted cancer, mastocytosis, and inflammatory disease models, but not for broad-spectrum kinase assays or protocols requiring aqueous or ethanol solubility.

• BRD4770: G9a Inhibitor Workflow for Cancer Research

  2026-09-03

  BRD4770 is a practical G9a histone methyltransferase inhibitor for connecting H3K9 methylation changes with senescence, cell death, and cancer-cell growth. This guide translates its PANC-1 use case into a controlled workflow and shows how to extend the assay logic to chromatin-pathway studies without confusing exploratory conditions with validated potency.

• HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) in Plaques

  2026-09-03

  Discover how the HyperFluor™ 594 Goat Anti-Rabbit IgG (H+L) Antibody can translate causal atherosclerosis findings into spatially resolved immunofluorescence assays. This guide connects fluorophore selection, controls, multiplexing, and plaque biology for more defensible detection of rabbit primary antibodies.

• Protease Inhibitor Cocktail for p53 Assays

  2026-09-02

  Protect p53, MLF2, USP7, and protein complexes during extraction with an EDTA-free, broad-spectrum formulation. This workflow shows how to adapt a 200X DMSO stock for Western blotting, co-immunoprecipitation, phosphorylation-sensitive assays, and colorectal cancer research.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-09-02

  Cy3 Goat Anti-Mouse IgG (H+L) Antibody is a fluorescent mouse IgG detection antibody for visualizing mouse primary antibodies in immunofluorescence, flow cytometry, and western blot workflows. It should be used for research assays after local optimization, not assumed to be validated for diagnostic testing, live-cell exposure, or immunohistochemistry without additional compatibility checks.

• Lapatinib: From Kinase Potency to Phenotype

  2026-09-01

  Lapatinib research is most informative when biochemical inhibition, receptor context, and tumor-cell phenotypes are interpreted together. This article develops an assay framework for GW572016 that clarifies target engagement, HER2-associated cancer research, and phenotype-first findings in triple-negative models.

• Imatinib hydrochloride Research Workflow Guide

  2026-09-01

  Build more informative kinase assays with Imatinib hydrochloride by separating biochemical potency, cellular response, and pathway-specific target engagement. This workflow also shows how the reference study’s kinase–phosphatase insight can improve interpretation without assuming that p38α findings directly validate imatinib.

• Hexose Diphosphate: Metabolic Assay Workflows

  2026-08-31

  Hexose diphosphate provides a water-compatible way to perturb glycolytic metabolism in cellular, ex vivo, and cardiovascular ischemia workflows. This guide connects practical dosing and handling decisions with emerging evidence that metabolic intermediates can shape inflammatory signaling, while clearly separating validated findings from testable hypotheses.

• Dual HER2/VEGFR2 Targeting in Breast Cancer Metastasis

  2026-08-31

  The reference study examines whether combining Lapatinib with Telatinib can suppress metastatic and angiogenic phenotypes in the HER2-negative MDA-MB-231 triple-negative breast cancer model. Its main contribution is the identification of reduced invadopodia formation, cell proliferation, and two-dimensional tube formation after single-agent and combination treatment, while also highlighting the need to distinguish phenotype-level activity from confirmed receptor engagement.

8370 records 3/558 page Previous Next 12345 下5页 Last page